Skip to main content
Clinical Trials/NCT06207279
NCT06207279
Recruiting
Not Applicable

Preliminary Study on the Development and Reliability and Validity of Attention Rating Scale

Peking University Sixth Hospital1 site in 1 country240 target enrollmentSeptember 28, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
Peking University Sixth Hospital
Enrollment
240
Locations
1
Primary Endpoint
Developing Attention Rating Scale(ARS)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This study, based on preliminary experimental results, literature review, and expert consultations, developed the Attentional Rating Scale (ARS). The aim was to rapidly assess participants' attention and potential influencing factors. The research focused on the scale's reliability and validity among healthy adults. Additionally, the Attention Network Test (ANT) served as the gold standard for evaluating attention. The study attempted to identify correlations between various dimensions of attention and the three attentional networks.

Detailed Description

1. To adiministrate 60 healthy subjects to evaluate internal consistency reliability. 2. To choose 20 cases for ARS retesting 7 days after the first ARS evaluation. 3. To evaluate the split half reliability through the Spearman Brown coefficient. 4. To apply principal component analysis for structural validity analysis. 5. Using the Attention Network Test (ANT) and Toronto Hospital Alertness Test (THE) as gold standards, the Pearson correlation coefficient was used for criterion validity analysis. 6. To administrate 60 patients with MDD, ADHD and insomnia disorder testing the discrimination validity of ARS.

Registry
clinicaltrials.gov
Start Date
September 28, 2023
End Date
December 31, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Peking University Sixth Hospital
Responsible Party
Principal Investigator
Principal Investigator

Xueqin Wang

Principle Investigator

Peking University Sixth Hospital

Eligibility Criteria

Inclusion Criteria

  • Major Depressive Disorder (MDD) or attention deficit hyperactivity disorder (ADHD) diagnosed according to DSM-5, or Chronic Insomnia Disorder diagnosed according to ICSD-3
  • Ages between 18 and 60 years old
  • Right-handed
  • Educational level ≥5 years or IQ ≥90, capable of understanding and reading Chinese.

Exclusion Criteria

  • Currently diagnosed with any other DSM-5 mental disorders (according to MINI 7.0) or ICSD-3 sleep-wake disorders, apart from MDD, ADHD or insomnia disorder
  • Currently and past history of neurological disorders and physical illnesses with subjectives
  • Consumed alcohol in the week preceding the enrollment
  • Using antidepressants, antipsychotics, mood stabilizers, or other central nervous system-acting drugs for at least 4 weeks in the current episode
  • Undergoing any physical treatments such as ECT, neuromodulation therapy or Traditional Chinese Medicine treatment in the past 6 months
  • Refused to sign the informed consent form

Outcomes

Primary Outcomes

Developing Attention Rating Scale(ARS)

Time Frame: 3 months

The Attention Assessment Scale is developing as a tool to assess attention ability designed for self-rating scale. Its purpose is to swiftly evaluate the attention levels of adults. There are 30 items in ARS. The minimum value is 1 and maximum value is 5, and the higher scores mean a better outcome for attention ability.

Reliability and Validity of the Attention Assessment Scale.

Time Frame: 2 years

Reliability 1. Cronbach α of ARS should be above 0.8 that means good reliability. 2. The intra group correlation value for retesting reliability should be above 0.8 that means good retesting reliability. Validity 1. The split half reliability measured and factor analysis to test constuctive validity of ARS. 2. The correlation coefficient r with ANT and the correlation coefficient r with THAT should be statistic significant, that means good validity of attention ability for Attention Assessment Scale.

Study Sites (1)

Loading locations...

Similar Trials